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Abstract
Mesenchymal stem cells from human adipose tissue (hASCs)
are proposed as suitable tools for soft tissue engineering and
reconstruction. Although it is known that hASCs have the
ability to home to sites of inflammation and tumor niche, the
role of inflammatory cytokines in the hASCs-affected tumor
development is not understood. We found that interferon-c
(IFN-c) and/or tumor necrosis factor-a (TNF-a) prime hASCs to
produce soluble factors which enhance MCF-7 cell line malig-
nancy in vitro. IFN-c and/or TNF-a-primed hASCs produced
conditioned media (CM) which induced epithelial to mesen-
chymal transition (EMT) of MCF-7 cells by reducing
E-Cadherin and increasing Vimentin expression. Induced EMT
was accompanied by increased invasion, migration, and uro-
kinase type-plasminogen activator (uPA) expression in MCF-7
cells. These effects were mediated by increased expression
of transforming growth factor-b1(TGF-b1) in cytokines-primed
hASCs, since inhibition of type I TGF-b1 receptor on MCF-7
cells and neutralization of TGF-b1 disabled the CM from
primed hASCs to increase EMT, cell migration, and uPA
expression in MCF-7 cells. Obtained data suggested that IFN-
c and/or TNF-a primed hASCs might enhance the malignancy
of MCF-7 cell line by inducing EMT, cell motility and uPA
expression in these cells via TGF-b1-Smad3 signalization,
with potentially important implications in breast cancer pro-
gression. VC 2016 IUBMB Life, 68(3):190–200, 2016
Keywords: adipose tissue mesenchymal stem cells; MCF-7; inflammatory
cytokines; EMT; urokinase type-plasminogen activator
Introduction
Beside their inherent ability to home to injured tissues, mesen-
chymal stem cells (MSCs) migrate toward tumors and partici-
pate in tumor stroma formation (1). MSCs interact with cells
within tumor microenvironment, such as tumor-associated
fibroblasts (TAFs), endothelial cells, adipocytes and macro-
phages, and therefore the proangiogenic, antiapoptotic and/or
immunomodulatory properties of MSCs may modulate tumor
growth and development, as well as interactions of tumor cells
with factors of immune systems (2–5).
Breast cancer is one of the most commonly diagnosed can-
cers, and the second leading cause of cancer-related death in
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women (6). The most abundant tissue in breast region is mam-
mary adipose tissue constituted by resident mature adipocytes
and progenitor cells, mainly preadipocytes and adipose tissue
mesenchymal stem cells (hASCs) (7–9). Today it is clear that
hASCs, found in the circulation of breast cancer patients and
in stroma of primary breast carcinomas (8–11) do not have a
passive role in the breast tumor surrounding niche (12), but
they are involved in the pathogenesis, as potential suppressors
(13) or promoters (14) of tumor growth.
Crosstalk between tumor cells and adjacent MSCs, includ-
ing hASCs, is regulated through network of numerous soluble
factors like cytokines, chemokines and growth factors, which
affect the extracellular matrix remodeling, angiogenesis and
epithelial to mesenchymal transition (EMT) of tumor cells, ena-
bling them to form new tumors at distant sites (10,15–17). The
process of EMT can be induced by various stimuli, including
tumor-stromal cell interactions, hypoxia, cytokines and growth
factors; such as transforming growth factor-b (TGF-b1)
(18,19). The development of EMT may favor the capacity of
cancer cells to acquire motility, through loss of cell-cell adhe-
sion, downregulation of E-cadherin and positive expression of
mesenchymal markers (20,21), thus providing the initial can-
cer cell with invasive and metastatic properties. Metastasis is
also influenced by activity of extracellular matrix proteinases,
including urokinase-type plasminogen activator (uPA) enzyme,
that regulate cancer cell migration and invasion, essential
steps in the process of metastasis. Therefore, high protein level
of uPA is considered as prognostic marker associated with
high metastasis risk (10,17,22).
It is believed that inflammatory cells infiltrated within
tumor stroma may influence tumor progression, interplaying
with tumor cells and other cells within the microenvironment,
having anti-tumorigenic or pro-tumorigenic role (23,24). Simi-
larly, the proinflammatory cytokines secreted by immune cells,
such as interferon (IFN)-c and tumor necrosis factor (TNF)-a,
have been shown to express different effects on tumor cells,
acting either as tumor suppressors (25) or as tumor promoters
(26–28). Although the influence of inflammatory cytokines on
cancer cells is well recognized, it is less known how these pro-
teins modulate MSCs paracrine regulation of breast cancer
cells properties. In this study, we aimed to test our hypothesis
that inflammatory cytokines activate hASCs to produce soluble
factors, such as TGF-b1, which modulate EMT, motility and
uPA expression in the low-invasive human breast cancer cell
line MCF-7. Our findings showed that inflammatory cytokines
can educate ASCs to adopt malignancy-promoting features.
Experimental Procedures
Non-Enzymatic Isolation of hASCs and Cells
Cultivation
hASCs were isolated from adipose tissue samples obtained
during surgical procedures from the Institute for Oncology and
Radiology of Serbia, Belgrade, in accordance with ethical
standards of the local ethical committee and the Declaration of
Helsinki with informed consent obtained from the study sub-
jects. hASCs were isolated by adjusted non-enzymatic method
previously reported (29). In short, to remove blood and impur-
ities, the tissues were extensively washed with Phosphate Buf-
fered Saline (PBS, Sigma Aldrich) supplemented with 1% Peni-
cilin/Streptomycin (P/S) and 0.25 mg/mL Amphotericin B (both
from PAA, Linz, Austria). The tissues were minced to small
pieces (3 3 3 mm) with surgical scissors and put into 25 cm2
culture flask (Greiner Bio-One International, GmbH) for 20 min
to attach in humidified atmosphere at 37C with 5% CO2
(standard conditions). Then, 3 mL of DMEM (Sigma-Aldrich,
St.Louis, MO) supplemented with 20% Fetal Calf Serum (FCS)
(Gibco, Life Technologies), 1% Hepes (PAA, Linz, Austria) and
1% P/S was added to flasks, disabling adipose tissue pieces to
float. These pieces were incubated for 10 days, until first cells
migrated, attached to plastic and formed colonies, when pieces
were thrown out, with further medium change every 2 to 3
days. After achieving 80 to 90% confluence, hASCs were
detached by 0.25% trypsin-EDTA solution (Gibco), replated at
concentration 104 cells/cm2 and cultivated in standard condi-
tions in growth medium (GM) containing DMEM supplemented
with 10% FCS, 1% Hepes and 1% P/S. All experiments were
performed using hASCs between passage 2 and 6.
Human breast carcinoma cell line (MCF-7), was purchased
from The American Type Culture Collection (ATCC, HTB-22),




According to the minimal criteria for defining MSCs, recom-
mended by International Society for Cellular Therapy (ISCT),
the expression of CD90, CD44, CD73 (obtained from R&D Sys-
tems, Minneapolis, MN), CD105 (Invitrogen, Carlsbad, CA), and
additional hematopoietic cells markers CD34 (Dako, UK) and
HLA-DR (Invitrogen) was analyzed. For cell-surface molecule
analysis, 2 3 105 hASCs were washed in cold PBS supple-
mented with 0.5% BSA (Sigma-Aldrich), and labeled with phy-
coerythrin (PE) or fluorescein isothiocyannate (FITC) conju-
gated antibodies. To determine the level of nonspecific
binding, fluorochrome-conjugated isotype control antibodies
(R&D Systems) were used. Flow cytometry was performed
using CyFlow CL (Partec, M€unster, Germany).
For the analysis of multilineage differentiation potential,
hASCs were seeded in 24-well plates at concentration of 2 3 104
cells/well in GM and incubated under standard conditions. The
GM was replaced every 2 to 3 days. After reaching 80% of conflu-
ency, cells were incubated in specific differentiation medium.
Osteogenic differentiation medium contained GM supplemented
with 10 nM dexamethasone (AppliChem), 200 mM ascorbic
acid-2-phosphate (Galenika, Belgrade, Serbia) and 10 mM b-
glycerophosphate (Sigma–Aldrich). Calcified deposits and extrac-
ellular matrix mineralization were visualized by Alizarin red
(2%) staining assay performed after 21 days.
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To determine the hASCs capacity for adipogenic differen-
tiation, the presence of intracellular lipid droplets in cell cul-
tures was assessed by staining with Oil Red O (Merck, Darm-
stadt, Germany) after 21 days of cultivation in GM
supplemented with 100 mg/mL isobutylmethylxanthine (IBMX;
Sigma–Aldrich), 1 mM dexamethasone and 10 mg/mL insulin
(Sigma-Aldrich). hASCs were also cultivated in chondrogenic
differentiation medium consisting of GM supplemented with 5
ng/mL transforming growth factor (TGF-b) (R&D Systems),
200 mM ascorbic acid-2-phosphate and 10 nM dexamethasone
for 21 days. Chondrogenic differentiation was assessed via
proteoglycans stained with Safranin O (Merck). Cells were ana-
lyzed and photographed using a light microscope (Olympus,
Japan).
Conditioned Media Preparation
Conditioned media (CM) from hASCs were prepared and
adjusted as previously described (30,31). Briefly, hASCs were
primed with 50 ng/mL of IFN-c and/or 20 ng/mL of TNF-a
(both from Invitrogen) for 24 h, and after extensive washing
with PBS were cultivated in GM without cytokines for addi-
tional 24 h in standard conditions. CM were then collected and
subjected to centrifugation at 1,400 rpm for 5 min and filtered
by using 0.20 lm filter. CM were named according to cells
treatment: CM 0, CM IFN/TNF, CM IFN and CM TNF.
Invasion and Wound Healing Assay
Transwell systems with 8.0 lm pore polycarbonate filters
(Greiner Bio-One) were used for evaluation of the invasion
capacity of tumor cells. MCF-7 cells were seeded at concentra-
tion 104 cells per transwell in 200 lL of growth medium in the
upper chamber with membranes precoated with fibronectin
(10 lg/mL). Growth medium (0.5 mL), or CM as chemoattrac-
tant were added in lower chamber. After 6 days, cells from
upper compartment were cleaned with a cotton swab to
remove the non-invading cells. Cells attached to the lower side
of the membrane were fixed by immersing the transwells into
ice-cold methanol. After washing with PBS, transwells were
turned upside down and membranes were stained with 0.1%
Crystal-violet. Stained cells were observed by inverted micro-
scope. Quantification was performed by resolving crystal-violet
in isopropanol and optical density was measured at 540 nm
using an automatic reader for microtiter plates (Labsystems
Multiskan PLUS, Finland).
MCF-7 at concentration 2 3 104 cells/well were seeded in
fibronectin (10 lg/mL, Sigma Aldrich) precoated 24-well plates
(Greiner Bio-One International) and cultured in GM in stand-
ard conditions. Wound healing assays were performed as pre-
viously described (32). Migration of the cells was documented
after 6 days of cultivation (details specified in Results) by
inverted light microscope and quantified using TScratch soft-
ware (Computational Science and Engineering Laboratory,
Swiss Federal Institute of Technology, ETH Z€urich, Z€urich,
Switzerland).
Immunofluorescence Labeling
Cells (5 3 104 cells/coverslip) were allowed to adhere for 24 h
in standard conditions, and then treated as described in
Results. Immunofluorescent labeling was performed as previ-
ously described (32). Briefly, cells were fixed in 4% parafor-
maldehyde, permeabilized in 0.1% Triton-X100 (Sigma-
Aldrich), and then immunolabeled with primary antibodies:
mouse anti-TGF-b1 (dilution 1:100, Abcam, UK, kindly pro-
vided by dr. Djurdjica Jovović, Laboratory for Cardiovascular
Physiology, Institute for Medical Research, Serbia), rat anti-E-
cadherin (dilution 1:1,000, from Sigma-Aldrich), mouse anti-
Vimentin (dilution 1:100, from Santa Cruz Biotechnology, CA)
and rabbit pSmad3 (1:100, Santa Cruz Biotechnology). Sam-
ples incubated in 1% BSA in PBS served as negative control.
After appropriate incubation (indicated in Results), cells were
washed three times with PBS and incubated with the corre-
sponding FITC/TRITC-coupled secondary antibodies (dilution
1:100, both from Sigma-Aldrich) and 1 lg/mL of DAPI (Sigma-
Aldrich) for nucleus labeling for 1 h at room temperature.
Mounted cells were analyzed using an epi-fluorescent micro-
scope (Olympus, Japan).
Western Blot Assay
Cells (1 3 105 cells/well) were seeded in six-well plates
(Greiner Bio-One International) and, after reaching 80% con-
fluence in standard conditions, treated as indicated in Results.
Cell monolayers were lysed in RIPA buffer (1% NP-40, 0.1%
SDS, 1mM EDTA, 50 mM NaF, 1% sodium deoxycholate) with
10 mM of sodium orthovanadate and proteinase inhibitors.
Samples were centrifuged and protein concentrations in super-
natants were determined by BCA assay (Serva, GmbH). Next,
10 lg of samples were subjected to SDS-PAGE (10%) in reduc-
ing conditions, and then proteins were electrotransferred to
0.45lm pore size nitrocellulose membrane (AppliChem). Spe-
cifically, when secreted levels of TGF-b were analyzed, 100 lL
of GM/CM were applied. Membranes were blocked in 5% skim
nonfat milk (Sigma Aldrich) in solution of Tris Buffered Saline
with 0.05% Tween 20 for 1 h and then incubated with primary
antibodies: mouse anti-TGFb1 (dilution 1:1,000, Abcam),
mouse anti-a-tubulin and rat anti-E-cadherin (dilution 1:1,000,
both from Sigma Aldrich), mouse anti-Vimentin (dilution
1:1,000), rabbit anti-uPA (dilution 1:500), rabbit anti-pSmad3
(dilution 1:500) and rabbit anti-tSmad3 (dilution 1:500) (all
both from Santa Cruz Biotechnology). Immune complexes were
detected using corresponding anti-rat (Sigma Aldrich), anti-
mouse (Sigma Aldrich) and anti-rabbit (Santa Cruz Biotechnol-
ogy) secondary antibodies (all dilutions 1:1,000) coupled to
horseradish peroxidase (HRP) and lightened with chemilumi-
nescent substrate (Serva Electrophoresis). Protein bands were
detected and quantified.
Zymography Assays
To analyze cell-associated uPA activity, MCF-7 (105 cells/well)
were plated in six-well plates and after reaching confluence
treated with GM or CM for 6 days in standard conditions. After
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washing twice with PBS, cells were lysed with 300 lL of lysis
buffer (0.5% Triton X-100 in 0.1 mol/L Tris-HCl, pH 8.1). Cell
lysates were centrifuged at 10,000 rpm for 15 min and protein
concentrations were determined by BCA assay. uPA determi-
nation was assayed as described (32). Briefly, protein samples
(10 lg) were subjected to SDS-PAGE (10%) under non-
reducing conditions, and electrophoresis running gels were
washed twice (30 min) in 2.5% Triton X-100. Then gels were
laid over substrate gel composed of 1% agarose, 0.5% casein,
1.5 M Tris-HCl, pH 8.8, 1.0 M Tris HCI, pH 6.8, 10 mM CaCl2
and 2 lg/mL plasminogen (Sigma-Aldrich). The gels were
placed in a humidified atmosphere and incubated overnight at
37C. Clear bands corresponding to uPA activity were detected
and quantified.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
After specific cell treatments, indicated in Results, total RNA
was obtained using TRIzol (Invitrogen) and complementary
DNA was generated from 2 lg of RNA by RevertAidTM H Minus
First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham,
MA), using oligo (dT) as a primer. The primer sets (Invitrogen)
are described in Table 1. PCR products were obtained after 33
cycles of amplification with adjusted annealing temperature
ranging from 49 to 55C. Amplicons were resolved in 1.5%
agarose gel and stained with ethidium bromide. GAPDH was
amplified as a control for the amount of cDNA present in each
sample.
Densitometry Analysis and Statistical Analysis
The intensity of the bands on gels obtained by Western blot,
zymography and RT-PCR was quantified using ImageMaster
TotalLab v1.11 software. Values are expressed as relative to
control (given the value 1). Statistical significance was eval-
uated by Student’s t-test, using the GraphPad Prism 5, with
value P<0.05 considered as significant.
Results
Inflammatory Cytokines Prime hASCs to Express
Increased Levels of TGF-b1 and Activate TGF-b1
Signaling in MCF-7 Cells
Mesenchymal origin of isolated cells was confirmed by analysis
of their immunophenotype and trilineage differentiation
capacity. Positive expression of CD90, CD44, CD73, CD105 and
negative expression of CD34 and HLA-DR in hASCs was
observed (Fig. 1A). Also, hASCs showed ability for osteogenic,
adipogenic and chondrogenic differentiation (Fig. 1B). Given
that TGF-b is recognized as an immunosuppressive factor with
dual role in cancer development, acting as tumor suppressor
in early stages and as tumor promoter in late stages of cancer
(33), we investigated whether inflammatory cytokines affect
the expression of TGF-b1 in hASCs. We found that IFN-c and/
or TNF-a increased the expression of TGF-b1 both at mRNA
and protein level in hASCs, as well as in their conditioned
media (Figs. 1C and 1D) in comparison to non-primed hASCs.
Additionally, we investigated the capacity of CM derived from
hASCs to stimulate Smad3 signaling in MCF-7 cells, a canoni-
cal signaling pathway activated by TGF-b1 in tumor cells (34).
Our results showed that CM derived from cytokine-primed
hASCs (CM IFN/TNF, CM IFN, CM TNF) enhanced Smad3 phos-
phorylation (Fig. 2A), as well as pSmad3 nuclear localization
in MCF-7 cells (Fig. 2B) when compared to MCF-7 cells culti-
vated in GM or CM 0. These results indicated the involvement
of TGF-b1 in hASCs and MCF-7 cells crosstalk.
Conditioned Media from Inflammatory
Cytokines-Primed hASCs Enhance EMT of MCF-7
Cells via TGF-b1
One of the hallmarks of tumor progression is the induction of
EMT in epithelial cancer cells (18). Since MSCs were shown to
have the capability to increase tumor malignancy (1), our next
goal was to investigate whether CM from IFN-c- and/or TNF-a-
primed hASCs induce EMT in MCF-7 cells. To address this, we
analyzed the expression of adherent junctions E-Cadherin, a
marker for epithelial phenotype, and intermediate filament
Primer sets used in experiments






TGF-b1 GGGACTATCCACCTGCAAGA CCTCCTTGGCGTAGTAGTCG 239 51
E-cadherin GGAAGTCAGTTCAGACTCCAGCC AGGCCTTTTGACTGTAATCACACC 290 49
Vimentin AGATGGCCCTTGACATTGAG TCTTGCGCTCCTGAAAAACT 345 55
uPA GCAGGAACCCAGACAACCG GACCCAGGTAGACGATGTAG 357 52
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 452 52
TABLE 1
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Mesenchymal stem cells characteristics and expression of TGF-b1 in isolated hASCs. (A) Immunophenotype of hASCs, (B)
osteogenic, adipogenic and chondrogenic differentiation potential of hASCs. (C) Confluent hASCs were treated with IFN-c (50
ng/mL) or/and TNF-a (20 ng/mL) for 24 h and total proteins and mRNA were isolated or hASCs were subjected to immunofluo-
rescence analyses. Conditioned media were collected as it is described in Materials and Methods. Relative TGF-b expression in
hASCs was determined by Western blot and RT-PCR. a-tubulin and GAPDH were used as a gel loading controls for WB and
RT-PCR, respectively. (D) Immunofluorescent labeling of TGF-b1 (red) in hASCs. Cell nuclei were labeled with DAPI (blue). Rep-
resentative histograms, blots, gels and photos are shown. Graph represents TGF-b1 expression level (means6SEM from three
experiments). Statistically significant changes in expression relative to control (GM): **P<0.01, ***P<0.001.
CM derived from cytokines-primed hASCs enhanced Smad3 signalization in MCF-7 cells. MCF-7 cells were cultivated in GM or
CM for 24h and total proteins were isolated or cells were subjected to immunofluorescence analyses. (A) Relative level of phos-
phorylated Smad3 was determined by Western blot. Smad3 was used as equal protein amount control. (B) Immunofluorescent
labeling of phosphorylated Smad3 (green) in MCF-7 cells. Cell nuclei were labeled with DAPI (blue). Representative blots and
photos are shown. Graph represents the pSmad3/Smad3 level (means6SEM for three independent experiments). Statistically
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Vimentin, as a mesenchymal marker. Immunofluorescent
labeling showed that CM from IFN-c- and/or TNF-a-primed
hASCs reduced E-Cadherin expression at sites of cell-cell con-
tacts in comparison to cells grown in GM and CM 0, where
E-Cadherin was localized mainly within intercellular contacts
(Fig. 3A). At the same time, CM, derived from primed hASCs,
enhanced Vimentin protein expression (Fig. 3A), thus giving
MCF-7 cells a mesenchymal phenotype. Additionally, we dem-
onstrated that indirect co-culture of MCF-7 and cytokines-
primed hASCs stimulated EMT in MCF-7 cells, in comparison
to MCF-7 cells cultivated alone or with unprimed hASCs (Sup-
porting Information Fig. S1A).
These results were confirmed by Western blot analysis
of total cell E-cadherin expression (Fig. 4A), while RT-PCR
showed that CM from both primed and unprimed hASCs
decreased E-cadherin mRNA expression in comparison to
GM (Fig. 4B). Similarly, CM derived from primed hASCs,
enhanced the Vimentin protein expression (Fig. 4C), while
CM from both unprimed and primed hASCs increased
Vimentin mRNA expression when compared to GM (Fig. 4D).
To investigate whether TGF-b1 was involved in the
observed effects of CM of cytokines-treated ASCs on EMT in
MCF-7 cells, we included a chemical inhibitor for type I TGF- b
receptor (ALK5/TGF-bRI), SB505124, as well as neutralizing
anti-TGF-b1 antibody in our next experiments. Results showed
that 6 days cultivation of MCF-7 in CM derived from hASCs, in
the presence of SB505124 (Fig. 3B) or anti-TGF-b1 antibody
(Fig. 3C) failed to induce EMT in MCF-7 cells. Similar, pres-
ence of SB505124 abolished stimulatory effects of cytokines-
primed hASCs on EMT of MCF-7 cells in indirect co-culture
system (Supporting Information Fig. S1B). Also, SB505124
abolished the inhibitory effects of CM on E-cadherin protein
and mRNA expression (Figs. 4A and 4B), as well as its
stimulatory effects on Vimentin protein and mRNA expression
CM derived from cytokines-primed hASCs induced epithelial to mesenchymal transition in MCF-7 cells. After cultivation in GM
or CM for 6 days, MCF-7 cells were subjected to double-immunofluorescence labeling. Cells were incubated with primary anti-
bodies mixture overnight at 4 C. Expression of E-cadherin (green) and Vimentin (red) in MCF-7 cells cultivated in (A) GM or
CM; (B) GM or CM in presence of SB505124 inhibitor (2 mM, Sigma-Aldrich); (C) GM/CM supplemented with neutralizing anti-
TGFb1 antibody (1 mg/mL, R&D Systems) 40 min prior to treatment of MCF-7 cells. Cell nuclei were labeled with DAPI (blue).
Representative photos for at least three independent experiments performed in triplicate are shown.
FIG 3
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(Figs. 4C and 3D). These results indicate that inflammatory
cytokines, via inducing TGF-b1 expression in hASCs, induce
EMT of MCF-7.
Conditioned Media from Inflammatory Cytokines-
Primed hASCs Enhance Invasion, Migration and uPA
Expression in MCF-7 Cells via TGF-b1
With the increment of cell malignancy, cancer cells acquire
mesenchymal phenotype that allows them to migrate and
invade neighboring areas (35,36). We further analyzed
whether CM from inflammatory cytokines-primed hASCs stim-
ulate MCF-7 invasion and migration. In the invasion assay, CM
derived from cytokine-primed ASCs increased the invasion
capacity of MCF-7 cells, in comparison to GM and CM 0 (Figs.
5A and 5B). Addition of SB505124 inhibitor abolished stimula-
tory effects of CM on MCF-7 cells invasion capacity. Also, we
demonstrated that in indirect co-culture, cytokines-primed
hASCs stimulated invasion of MCF-7 cells in compare to MCF-7
cultivated alone or with unprimed hASCs, while presence of
SB505124 abolished stimulatory effects of cytokines-primed
hASCs (Supporting Information Figs. S2A and S2B). We further
performed a wound healing assay, and, as shown in Figs. 5C
and 5G, the CM from hASCs increased the capacity of cells to
close wounded areas. Moreover, CM derived from cytokine-
primed ASCs had higher stimulatory effect on migration of
MCF-7 in comparison with CM 0. To determine whether the
effects of CM are mediated by TGF-b1 present within, we
investigated the impact of TGF-b1 receptor inhibition or neu-
tralizing anti-TGF-b1 antibody, on the stimulation of MCF-7
cells migration. Results showed that presence of SB505124
inhibitor and anti-TGF-b1 antibody abolished the migration
inducing effects of CM on tumor cells (Figs. 5D, 5E, and 5G).
To investigate whether effects of ASCs-derived CM were medi-
ated by uPA activity in MCF-7 cells, we further evaluated the
migration capacity of these cells in the presence of BC-11
(inhibitor of uPA). Results showed that presence of uPA inhibi-
tor BC-11 abolished the stimulatory effects of CM on MCF-7
cells migration (Figs. 5F and 5G). Similar, we demonstrated in
indirect co-culture that hASC stimulated migration of MCF-7
cell in compare to control (MCF-7 alone), while the presence of
SB505124 inhibitor abolished these effects (Supporting Infor-
mation Figs. S2C and S2D).
Inhibition of TGF-b1 receptor reverted the effects of CM derived from hASCs on E-cadherin and Vimentin expression in MCF-7
cells. After cultivation of MCF-7 for 6 days in GM or CM, in the absence or presence of SB505124 (2 mM), (A, B) E-cadherin and
(C, D) Vimentin protein and mRNA expression were detected by Western blot and RT-PCR. a-tubulin and GAPDH were used as
a gel loading control for WB and RT-PCR, respectively. Representative immunoblots and gels are presented. Graphs represent
E-cadherin or Vimentin expression level (means 6 SEM for at least three experiments). Statistically significant changes in
expression relative to control (GM w/o SB505124): *P<0.05, **P<0.01, ***P<0.001, while relative to CM 0: ###P<0.001.
FIG 4
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As the expression of ECM proteinases, such as uPA, is
essential for migration of tumor cells (37,38), we next deter-
mined whether changes in uPA expression occur in MCF-7
cells after treatment with CM. Furthermore, as TGF-b1 has
been demonstrated as a potent inductor of uPA expression in
cancer cells (33), we determined whether TGF-b1 is implicated
in the enhancement of uPA expression by CM. We showed that
increased uPA levels correlate with enhanced cell migration
(Figs. 5 and 6). When compared with cells cultured in GM
only, MCF-7 cells treated with all CM, showed higher expres-
sion of cell-associated uPA, while inhibition of TGF-b1 receptor
on MCF-7 cells nullified the stimulatory effects of CM on cell-
associated uPA activity (Fig. 6A). As shown for invasion and
migration of MCF-7, CM 0 stimulates the activity of cell-
associated uPA in MCF-7 cells, however, in lesser extent than
CM IFN/TNF, CM IFN and CM TNF. Similarly, CM derived from
cytokines-primed hASCs stimulated uPA protein expression,
while inhibition of TGF- b1 receptor in MCF-7 abolished these
effects (Fig. 6B). Obtained results also showed that all CM
increased mRNA expression of uPA in MCF-7 cells and that
inhibition of TGF- b1 receptor on MCF-7 cells abolished these
effects (Fig. 6C). Taken together, these results confirmed the
role of TGF- b1 and uPA in the effects of inflammatory
cytokines-primed hASCs CM in enhanced invasion and migra-
tion capacity of MCF-7 cells.
Discussion
Adipose tissue is currently recognized as rich source of MSCs
which, owing to their stem cell properties, self-renewal and
differentiation ability, participate in tissue regeneration and
repair. MSCs within mammary adipose tissue represent one of
the major factors in mammary tissue development, but also in
tumorigenesis and progression of diverse breast cancer types
(39,40). Contrary to acute inflammation which has protective
role in tissue homeostasis, chronic inflammation could be
related to neoplastic processes and to all cancer development
stages, thus contributing to the complexity of inflammation
and cancer crosstalk (41–43). Inflammatory factors present in
tumor microenvironment render MSCs to adopt an immuno-
suppressive phenotype, thus recruiting more tolerogenic types
of lymphocytes, macrophages and myeloid-derived suppressor
cells to the tumor site. However, how inflammatory conditions
CM derived from hASCs enhanced MCF-7 cells invasion and migration. Invasion and migration level were determined by trans-
well system and wound healing assay, respectively, after cultivating MCF-7 cells for 6 days. (A and B) Invasion rate of MCF-7 cells
cultivated in GM or CM w/o SB505124. Scale bars 50 mm. Migration level of MCF-7 cells cultivated in (C) GM or CM; (D) GM or
CM in the presence of SB505124 inhibitor (2 mM) (E) GM/CM supplemented with neutralizing anti-TGFb1 antibody (1 mg/mL) 40
min prior to treatment of MCF-7 cells; (F) GM or CM in the presence of BC-11 (25 mM, Tocris Bioscience). Scale bars 100 mm. Rep-
resentative photos are shown. Graphs show means6SEM for three independent experiments performed in triplicate. Statistically
significant changes in invasion/migration rate relative to control (GM w/o SB505124 for invasion and GM at zero time T0 for
migration): *P<0.05, **P<0.01, ***P<0.001, while relative to CM 0: #P<0.05.
FIG 5
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affect the hASCs and cancer cells interplay is still not fully elu-
cidated. Here, we provide results which demonstrate that
proinflammatory cytokines (i.e. IFN-c and/or TNF-a) act on
hASCs in a way to promote expression and secretion of TGF-
b1 into conditioned media, which further increases the malig-
nancy of MCF-7 cells.
Pretreatment of MSCs with IFN-c and TNF-a has previously
been shown to upregulate TGF-b1 expression in bone marrow
MSCs (44), while its association with promotion of tumor
growth has been reported for IL-1a-treated mouse MSCs (45).
In addition, previously reported expression of membrane-
bound form of TGF-b1 in bone marrow MSCs induced by pres-
ent colorectal tumor cells (46) provided evidence that TGF-b1
expression in MSCs could be regulated by present tumor cells.
Our results are in accordance with mentioned results, adding
to the diversity of MSCs which are affected by inflammatory
cytokines in a similar way.
TGF-b in complex with its type I and type II receptors,
leads to activation of Smad proteins, with an important role in
the mammary development and tumorigenesis (33,47,48). We
showed that CM from cytokines-primed hASCs induced phos-
phorylation and nuclear translocation of Smad3 in MCF-7
cells, thus supporting previous findings which showed that
Smad3 phosphorylation can be induced by direct cell contacts/
interactions between bone marrow MSCs and colorectal can-
cer cells (46). Since CM derived from IFN-c and/or TNF-a-
primed ASCs were capable to stimulate Smad3 activation in
MCF-7 cells, it is plausible that, similar to its essential role in
TGF-b1-induced effects in epithelial cells (34), Smad3 activa-
tion may reflect the capacity of TGF-b1, present in the CM, to
stimulate EMT, cell migration and uPA expression in cancer
cells. As dual role of TGF-b in breast cancer development
depends on Smad3 mutations (47), further research would be
necessary to elucidate the role of Smad3 activation in EMT
and migration of MCF-7 cells.
TGF-b1 induces EMT-related phenotypic changes in epi-
thelial cells, as characterized by reduced expression of epithe-
lial markers, such as E-Cadherin, and increased expression of
mesenchymal markers, such as Vimentin (34,46,49,50).
Results of our study demonstrated that CM from IFN-c and/or
TNF-a-primed hASCs had the capacity to promote EMT of
MCF-7 cells via TGF b1, along with lower E-cadherin and
Inhibition of TGF-b1 receptor nullified the effects of hASCs-derived CM on increased uPA expression in MCF-7 cells. MCF-7 cells
were cultivated for 6 days in GM or CM in the presence or absence of SB505124. After treatment, zymography, Western blot and
RT-PCR were performed to detect the level of (A) cell-associated enzyme activity, (B) protein expression and (C) mRNA expres-
sion, respectively, of uPA in MCF-7 cells. a-tubulin and GAPDH were used as gel loading controls for WB and RT-PCR, respec-
tively. Representative blots and gels are shown. Graphs represent the activity or expression level of uPA (means 6 SEM for at
least three experiments). Statistically significant changes in expression relative to control (GM w/o SB505124): *P<0.05,
***P<0.001, while relative to CM 0 w/o SB505124: #P<0.05, ###P<0.001.
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higher Vimentin expression in these cells. These findings are
in accordance with previous data which demonstrated the sup-
porting role of human bone marrow MSCs in the EMT of hepa-
tocellular carcinoma cells (31).
Our results demonstrated that CM derived from hASCs
stimulated the migration and invasion capability of MCF-7 cells
via TGF b1. CM derived from cytokines-primed hASCs pos-
sessed higher stimulatory effect on migration of MCF-7 cells
than CM derived from non-primed hASCs, emphasizing the
role of inflammatory conditions in the effects of MSCs on
tumor development, which must be considered as crucial fac-
tors in the investigation of MSCs and tumor cells interaction.
We found that CM derived from primed hASCs increased the
production of uPA in MCF-7 cells via TGF b1. Although it was
previously reported that CM from MSCs affect EMT of tumor
cells via uPA-TGF b1 system (51), here we for the first time
demonstrated that inflammatory cytokines enhanced capacity
of hASCs-derived CM to increase motility and uPA expression
in MCF-7 cells via TGF b1.
Interestingly, CM derived from non-primed hASCs (CM 0)
modified the expression of E-cadherin, Vimentin and uPA at
mRNA level in MCF-7 cells, while it failed to modify their
expression at protein level, thus implying that inflammatory
cytokines are responsible for modulation of these markers at
protein level. All treatments applied, i.e. either IFN-c or TNF-a
alone, or their combination, induced comparable increase of
EMT, migration and uPA expression and no additive or syner-
gistic effects were observed with the combined treatments
with these cytokines.
In summary, priming of hASCs with inflammatory cyto-
kines enhances their ability to promote EMT, migration, inva-
sion and uPA expression in MCF-7 tumor cells. The results
indicate that all these features, which highly participate in
breast cancer cell malignancy and metastasis, are mediated,
at least in part, by TGF-b1, and point to the importance of the
inflammatory tumor microenvironment in educating the hASCs
to adopt the breast tumor-promoting characteristics.
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